diabetes

Health tech Lizzy Lawrence

STAT Plus: Software glitch caused Tandem insulin pumps to prematurely shut down, FDA warns

The Readout Elaine Chen

STAT Plus: A spending frenzy on obesity drugs

Biotech Elaine Chen

STAT Plus: Novo Nordisk’s move to discontinue an insulin leaves patients to ‘pick up the pieces’

Health Andrew Joseph

European regulators find no evidence of link between new obesity medicines and suicidal thoughts

Insurance Tara Bannow

STAT Plus: MassMutual is rolling out free genetic testing for members, a dicey area for life insurers

Pharma Elaine Chen

STAT Plus: Positive trial results set up obesity drug Wegovy for use against heart failure

Health tech Mario Aguilar

STAT Plus: Health tech investor Glen Tullman launches 62 Ventures, a new $100 million fund

Biotech Elaine Chen

STAT Plus: Parkinson’s disease may be helped by GLP-1 drug, new study finds

Health Annalisa Merelli

STAT Plus: GLP-1 generics would be dramatically cheaper than U.S. price of Ozempic, study shows, but still profitable

Health Elaine Chen

Ozempic-like drugs linked to low, but increased risk of post-endoscopy pneumonia, study finds

Health tech Katie Palmer and Mario Aguilar

STAT Plus: Digital tools for diabetes management did not deliver benefits that justify cost, new report finds

Health tech Katie Palmer and Lizzy Lawrence

STAT Plus: FDA clears first over-the-counter continuous glucose monitor

Health Elaine Chen

STAT Plus: FDA cracks down on websites that claim to sell chemicals in obesity drugs Wegovy, Zepbound

Health Elaine Chen

STAT Plus: Can Wegovy treat depression as well as obesity? New research looks to GLP-1 drugs for mental illnesses

Health Elaine Chen

GLP-1 drugs not linked to suicidal thoughts in FDA’s early review

Biotech Adam Feuerstein

STAT Plus: Structure Therapeutics GLP-1 pill cuts blood sugar, weight in early diabetes study

Politics John Wilkerson

STAT Plus: Sanders blames food companies for diabetes epidemic

Health tech Lizzy Lawrence

STAT Plus: Medtronic cancels $738 million acquisition of diabetes tech company EOFlow

D.C. Diagnosis Rachel Cohrs Zhang

STAT Plus: Diabetes ‘epidemic’ gets a Senate hearing

Pharmalot Ed Silverman and John Wilkerson

STAT Plus: A growing number of U.S. states, cities, and counties are suing insulin makers and PBMs

Biotech Annalisa Merelli

STAT Plus: What Eli Lilly’s Zepbound reveals about the intricate process of naming drugs today

Health Andrew Joseph

Type 2 diabetes prevention programs can work at large scale, study finds

Pharma Elaine Chen

STAT Plus: Novo Nordisk wants to be a cardiovascular company, too, with sights set on inflammation

Health tech Katie Palmer

STAT Plus: Patients loved Carbon Health’s diabetes program. That couldn’t save it

D.C. Diagnosis Rachel Cohrs Zhang

Medicare eligibility is tripping up the GOP presidential candidates

Politics Sarah Owermohle

STAT Plus: Senator floats new models to manage costs of weight loss drugs like Ozempic

Pharma Elaine Chen and Damian Garde

STAT Plus: Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound

Health Katherine MacPhail

Why preventative care is such a tough sell in the U.S., according to chronic disease experts

First Opinion David Panzirer

Insulin is increasingly affordable in the U.S. What about the rest of the world?